Go to deals
Healthcare

Thubilux Pharma SpA has received a structured loan of US$2.7 million from a leading Italian bank

Tubilux Pharma SpA has successfully raised funds through a structured loan from Cassa Depositi e Prestiti SpA and Banca Intesa San Paolo SpA to support an investment plan for a new production facility which has all the FDA requirements to enter the USA market.

Tubilux Pharma is a leading, privately-held ophthalmic and pharmaceuticals company that develops and markets a range of proprietary, over-the-counter, and branded generic products, with distribution in approximately 30 countries. The firm's customers are large multinational pharmaceutical companies that outsource their production of ophthalmic products to specialized manufactures through medium-term supply contracts (3-5 years).

Oaklins' team in Italy advised Thubilux Pharma SpA in the structuring, negotiation and closing of a long-term debt financing from a leading Italian bank, backed by Cassa Depositi e Prestiti.

Service
Funding, debt advisory & ECM
Parties

Talk to the deal team

 Federico  Cappa

Federico Cappa

Partner

Milan, Italy
Oaklins Italy
 Marie Gabriella  Sestini

Marie Gabriella Sestini

Associate

Turin, Italy
Oaklins Italy

Related deals

Groupe Nature acquires Winco
Consumer & Retail | Healthcare

Groupe Nature acquires Winco

Groupe Nature has signed an agreement with Nicolas Watine, founder and CEO of Winco, to acquire his stake in the comany. It specializes in the distribution of health and cosmetic products in parapharmacies affiliated to supermarket chains. This acquisition strengthens Groupe Nature’s position as a multi-channel specialist in the distribution of organic health products.

Learn more
Camelia pharmacy chain has been acquired by Medigate Management UAB
Consumer & Retail | Healthcare

Camelia pharmacy chain has been acquired by Medigate Management UAB

CGP Management UAB has sold the Camelia pharmacy chain (UAB Nemuno vaistinė and subsidiaries) to Medigate Management UAB.

Learn more
Shield Therapeutics has raised funds
Healthcare

Shield Therapeutics has raised funds

Shield Therapeutics Plc has completed a placing, subscription and open offer. The primary use of the funds is to launch Accrufer® in the USA.

Learn more